EHC Think Tank 2022 Activity Report
EHC publishes New Produce Report 2022 Vol. 2
EHC November 2022 Newsletter
BioMarin announced an additional serious adverse event in its gene therapy clinical trial for haemophilia A
BioMarin reports a serious adverse event for its phase I/II gene therapy trial for haemophilia A
February 4, 2022 – BioMarin’s gene therapy (valoctocogene roxaparvovec) for haemophilia A is currently in development and not yet licensed by regulators. BioMarin has completed dosing 134 patients in its phase 3 clinical study...
EAHAD Physiotherapists Network is looking for members
Three generations of carriers
EHC Now! Some things never change!
In this week’s EHC Now! we want to shine a light on some things that have not changed for our community despite the COVID-19 pandemic. Importance of seeking medical attention! It has been reported...